Pharma Foods International (TYO:2929) will establish Cadasil Drug Discovery Research Department in collaboration with the National Cerebral and Cardiovascular Center, according to a Wednesday filing on the Tokyo Stock Exchange.
Cadasil, a genetic vascular disease with no established cure, is linked to NOTCH3 gene mutations, leading to migraines, strokes, and dementia.
The National Cerebral and Cardiovascular Center, a research institute for cardiovascular diseases, is conducting Phase 2 clinical trials on adrenomedullin peptide as a potential treatment.
Pharma Foods will apply its expertise in peptide research to develop new therapies for the disease, aligning with its broader mission of advancing healthcare innovations.
Price (JPY): $940.00, Change: $-10, Percent Change: -1.05%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。